I love AGN's ultra low beta. It discourages the chart guys and program traders from trying to push prices around. This is a solid growth company whose value has not been clouded by the momentum traders. I am a buyer on this pullback.
I agree that this is a great move.
There is so much opportunity for effective treatments in the migraine space and AGN could become a major player with Botox and MAP Pharm.'s Levadex.
This is a solid strategic move that will pay off -- BIG time -- for AGN.
This should make AGN an even more attractive, plus exiting stock, when you add the recent acquisition of SkinMedica, coupled with last Friday's approval of Botox for over-active bladder -- OAB.
Management is positioning this company to lead, grow and shine for years to come.
What a bonanza!!